Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 668 for:    CARBON DIOXIDE AND arterial

Impact of Arterial CO2 Tension on Management and Outcome in Patients With Acute Hypoxemic Respirator Failure and ARDS (CO2 LUNG SAFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03415529
Recruitment Status : Completed
First Posted : January 30, 2018
Last Update Posted : August 14, 2019
Sponsor:
Information provided by (Responsible Party):
European Society of Intensive Care Medicine

Brief Summary:
There appears to be considerable variability in the approach physicians use to manage arterial carbon dioxide tensions, in patients in the early phases [first 48 hours] of ARDS (Acute hypoxemic respiratory failure and). A number of specific concerns exist, particularly the use of greater than needed inspired oxygen concentrations (potentially in 40% patients), and the proportion of hypocapnic patients in our cohort.

Condition or disease
Acute Severe Respiratory Failure Acute Respiratory Distress Syndrome

Detailed Description:

This study will address a number of specific concerns, including:

  1. the incidence of hypocapnia and hypercapnia;
  2. the factors (e.g. ventilatory mode) contributing to hypocapnia and hypercapnia;
  3. the impact of hypocapnia and hypercapnia on progression of ARDS, duration of ventilation, ICU stay, hospital stay and patient outcome;
  4. the impact of pH (respiratory versus metabolic cause) on outcome variables.

LUNG SAFE was a prospective observational study. There was not patient intervention. The current analysis is a secondary analysis of this existing database.

Data will be abstracted form the database on all patients meeting the inclusion criteria for ARDS (during the first 2 days from AHRF onset) for the following variables: Patient's demographic characteristics (age, sex) and chronic comorbidities, Arterial PCO2, pH in first 48 hours, Data on P/F ratio over course of illness, Duration of ventilation, ICU stay, hospital survival in patients identified as being exposed to hypocapnia (pCO2 < or = to 30mmHg) and hypercapnia (PCO2 > or = to 45mmHg); Main ventilatory variables: mode of ventilation, tidal volume, respiratory.

Descriptive statistics will include proportions for categorical and mean (standard deviation) or median (interquartile range) for continuous variables, according the data distribution. The amount of missing data in the LUNG SAFE database is low so no assumptions will be made for missing data.

In order to investigate the relationship between PaCO2 and management factors, the investigators will stratify study population according the presence or absence of hypercapnia and will evaluate differences in management factors, using appropriate statistical tests. In detail, proportions will be compared using chi-squared or Fisher exact tests and mean values were compared using T-test or Wilcoxon rank sum test, as appropriate. Shapiro-Wilks test will be used to assess normality in data distribution. Moreover, they will perform univariate and multivariable logistic regression models using hypercapnia as dependent variable. Stepwise regression approach with significance alpha levels of 0.05 (both for entry and retention) will be used to establish a set of independent predictors. Odds ratios (ORs) and 95% confidence intervals (CIs) will be reported as measure of association.

They will assess the association of hypercapnia with different outcomes (ARDS progression, duration of mechanical ventilation, ICU and hospital stay and mortality) using generalized linear regression models (Poisson or Logistic regression models, according outcome distribution) and adjusting the relationship with all possible confounders identified with stepwise approach. Results will be reported as ORs, incidence rate ratios and corresponding 95% CI.

Particular attention will be given to the relationship and interaction between pH and PaCO2.

Survival analysis (Kaplan-Meier approach) will be used to estimate the time of liberation from invasive mechanical ventilation, of ICU and hospital discharge, and of hospital mortality within 28 days of AHRF onset in patients with and without hypercapnia. Differences in survival time will be assess by Log-Rank test.


Layout table for study information
Study Type : Observational
Actual Enrollment : 4500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Incidence of Hypercapnia and Impact of Arterial CO2 Tension on Management and Outcome in Patients With Acute Respiratory Distress Syndrome (ARDS)
Actual Study Start Date : March 1, 2018
Actual Primary Completion Date : September 30, 2018
Actual Study Completion Date : December 30, 2018


Group/Cohort
4500 patients with ARDS
This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.



Primary Outcome Measures :
  1. Incidence [ Time Frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first ]
    The incidence of hypercapnia [i.e. PaCO2 > 45 mmHg] when ARDS arises


Secondary Outcome Measures :
  1. Severity [ Time Frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first ]
    The severity of hypercapnia [i.e. PaCO2 > 45 mmHg] when ARDS arises ARDS

  2. Hypercapnia [ Time Frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first ]
    Factors (e.g. ventilatory mode) contributing to hypercapnia in patients with ARDS

  3. Hypercapnia [ Time Frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first ]
    The impact of hypercapnia on outcome on the progression of ARDS

  4. pH ((potential of hydrogen) [ Time Frame: LUNG SAFE was a prospective observational study. Patients were followed until hospital discharge or day 90, whichever came first ]
    The impact of pH (respiratory versus metabolic cause) on outcome variables



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients over 18 years of age who fulfilled clinical criteria for ARDS and Acute Hypoxaemic respiratory failure were recruited into the LUNG SAFE trial (NCT02010073) that was published in JAMA, 2016 Jul 19;316(3):347).
Criteria

Inclusion Criteria:

  • All patients meeting criteria for ARDS. Fulfillment of criteria for Acute Hypoxaemic respiratory failure (AHRF) and fulfillment of Berlin criteria for ARDS during the first two days after AHRF onset.

Exclusion Criteria:

  • Age < 18

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03415529


Locations
Layout table for location information
Belgium
Guy Marie FRANCOIS
Brussels, Belgium
Sponsors and Collaborators
European Society of Intensive Care Medicine
Investigators
Layout table for investigator information
Principal Investigator: John LAFFEY National University of Ireland, Galway
Principal Investigator: Giacomo BELLANI University of Milano-Bicocca (Monza, Italy)

Publications:

Layout table for additonal information
Responsible Party: European Society of Intensive Care Medicine
ClinicalTrials.gov Identifier: NCT03415529     History of Changes
Other Study ID Numbers: CO2LUNGSAFE
First Posted: January 30, 2018    Key Record Dates
Last Update Posted: August 14, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by European Society of Intensive Care Medicine:
Lung
ARDS
Acute Respiratory Syndrome
Prognosis
Outcome Research
Respiratory infection
Sepsis
Organ failure
Hypercapnia
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Respiratory Insufficiency
Acute Lung Injury
Syndrome
Disease
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury